Abstract L-3-(3-Hydroxy-4-pivaloyloxyphenyl) alanine (1, NB-355) is a novel L-dopa prodrug. After oral administration with carbidopa in rats, 1 demonstrated 2.3 times longer duration (MRT) and 1.4 times larger bioavailability (AUC) on plasma L-dopa concentrations than those of L-dopa itself. Similar results were obtained in dogs. The prolonged profile of L- dopa was parallel to that of carbidopa, and the intact ester was undetectable in rat plasma. ...
